Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; purified water; maize starch; titanium dioxide; magnesium stearate; gelatin; colloidal anhydrous silica - the treatment of chronic cholestatic liver diseases.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - butorphanol tartrate (unii: 2l7i72ruhn) (butorphanol - unii:qv897jc36d) - butorphanol tartrate 10 mg in 1 ml - butorphanol tartrate nasal spray is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (see warnings), reserve butorphanol tartrate nasal spray for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) butorphanol tartrate nasal spray is contraindicated in: butorphanol tartrate nasal spray contains butorphanol, a schedule iv controlled substance. butorphanol tartrate nasal spray contains butorphanol, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. butorphanol tartrate nasal spray can be abused and is subject to misuse, addiction, and criminal diversion (see warnings). all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - butorphanol base as butorphanol tartrate; benzethonium chloride - parenteral liquid/solution/suspension - butorphanol base as butorphanol tartrate alkaloid active 10.0 mg/ml; benzethonium chloride ammonium-quaternary other 0.1 mg/ml - analgesic+musculoskeletal - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - anaesthetic - local/general | analgesic | pre-anaesthetic | anaesthetic premedicant | antipyretic | colic | general anaesthetic | immobiliser | local anaesthetic | muscle relaxant | premedication | sedative | spasmolytic | tranquilliser | travel sickness

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eliglustat tartrate, quantity: 100 mg (equivalent: eliglustat, qty 84.4 mg) - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; glycerol dibehenate; iron oxide yellow; gelatin; indigo carmine aluminium lake; titanium dioxide; mica; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - cerdelga is indicated for the long-term treatment of adult patients with gaucher disease type 1 (gd1).

United States - English - NLM (National Library of Medicine)

sentynl therapeutics, inc. - levorphanol tartrate (unii: 04wqu6t9qi) (levorphanol - unii:27618j1n2x) - levorphanol tartrate 2 mg - levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia levorphanol tartrate tablets are contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to levorphanol or any of the formulation excipients (e.g., anaphylaxis) [see wa

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nortriptyline, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; hypromellose; glycerol; maize starch; calcium phosphate; sunset yellow fcf aluminium lake - allegron is indicated for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - naloxone hydrochloride dihydrate, quantity: 400 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dilute hydrochloric acid - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval for listing of these goods as pharmaceutical benefits were approved as specified in the letter of 29 october 1992 from dr alex proudfoot. indications: for the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and the narcotic-antagonist analgesics such as nalbuphine, methadone and butorphanol. indications as at 8 january 2004: naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - nortriptyline, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; calcium phosphate; maize starch; glycerol; magnesium stearate - allegron is indicated for the treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - amphotericin b (amphotericin) -